Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Challenges in initiating antiretroviral therapy in 2010.Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTRole of atazanavir in the treatment of HIV infectionAtazanavir: its role in HIV treatmentCardiovascular complications in HIV management: past, present, and future.Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.Clinical pharmacology, efficacy and safety of atazanavir: a review.Renal toxicity associated with tenofovir use.Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.Ritonavir-boosted protease inhibitors in HIV therapy.Clinical management considerations for dyslipidemia in HIV-infected individuals.Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy.Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.HIV protease inhibitors: present and futureFrom lipodystrophy to cardiovascular disease: new insight into the management of HIV infectionChanges from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
P2860
Q26750406-1A3A871F-9AD7-4CCC-A260-FF2EE9FE9427Q27015850-32E260AB-C97E-42AB-B4F3-54F0459A2F69Q30227046-828F478E-5113-4AF0-8602-0E81B3E4629BQ33875048-47F534AC-9E43-4C6A-A0FA-8F9014586BCFQ34134900-AE4118E4-3E77-4242-B70C-7E1545A7C3AEQ34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432FQ34631149-9F73C7A0-50C3-4356-91B4-5A85939F4C0CQ35079510-64B2BCCD-3C58-4006-84AE-AFD9616D4463Q35091774-7B37143C-C6BA-4DAE-8EFD-771CFD59C3CFQ35186842-B56AC160-BF5D-4560-A2E3-85ED58FA7C9AQ35534418-6A1A6A9A-0499-4E8F-9E62-839F26648478Q35566732-5AA6180F-6A94-41E0-9DED-F926044EC310Q35963960-56C6F526-5059-466B-9FC8-E4ACCE4C4BE7Q36567732-4CD82A1E-83E1-4DD6-80CB-9D962E0C6F75Q36900010-BE01026F-0714-48FE-B0CB-26F553506C3DQ37230298-81191BE8-70D3-4363-8043-F33629A5F975Q37249418-94A4895F-B88E-4F27-B9F9-059D5D128296Q37353573-2161FF96-C92C-425A-80FE-63B93A7ABB57Q37428827-A37CC369-B93C-4AD7-8797-B25EFBE64DEAQ37622972-795AA851-FB29-4698-87F7-5B186D6CD049Q37729160-797471A7-7453-4D35-B5FC-EFBEAB4240D4Q37782179-57DBDB96-DFA9-48DC-B779-4140539F3756Q37866319-8C77ED2F-5057-4D69-BC62-D1303AA6133EQ37982205-5B9D7B4F-7424-4B24-ACCF-D91CBE457E63Q39412054-2645F450-73A2-4445-B721-2485889F8243Q41643193-7284BCCE-31C8-4581-BDE6-EA16087D8E58Q42269134-A9DF2DB1-0B85-496F-AFDE-FD7FE0C26E1EQ42787165-ABFEC452-14BC-40C8-8CF9-E94755BF9039Q43244208-B59CC5EE-6F5B-434D-BCF4-7A9CA5A3DF61Q43461603-434BAA48-903E-4247-A9F6-5BD7B9A3A2EBQ44564339-174DF3C9-57D6-45E4-99BA-714593C10AA5Q47754832-4C64FCE1-2A5F-4C1F-9AAF-7FB202850B8FQ58290794-FF73D23F-FB52-4343-82F3-377242FB9C23Q58798012-02EEBABB-DD30-4D91-83F4-EF085FD23A68Q58806292-271E40F4-331F-4B0F-A439-45AC4094279E
P2860
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@ast
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@en
type
label
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@ast
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@en
prefLabel
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@ast
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@en
P2093
P2860
P356
P1476
Fosamprenavir or atazanavir on ...... ion: 48-week results of ALERT.
@en
P2093
ALERT (COL103952) Study Team
C Tracey Lancaster
Edwin DeJesus
Gary E Pakes
Keith A Pappa
Kimberly Y Smith
Lisa L Ross
Margaret A Fischl
Qiming Liao
Winkler G Weinberg
P2860
P2888
P356
10.1186/1742-6405-5-5
P577
2008-03-28T00:00:00Z
P5875
P6179
1019344932